Next Article in Journal
Mineral Constituents Profiling of Ready-To-Drink Nutritional Supplements by Inductively Coupled Plasma Optical Emission Spectrometry
Previous Article in Journal
Modified Clerodanes from the Essential Oil of Dodonea viscosa Leaves
Previous Article in Special Issue
Potential of Thai Herbal Extracts on Lung Cancer Treatment by Inducing Apoptosis and Synergizing Chemotherapy
Open AccessArticle

Pharmacological Evaluation of the Anticancer Activity of Extracts and Fractions of Lannea barteri Oliv. (Anacardiaceae) on Adherent Human Cancer Cell Lines

1
Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State PMB 410001, Nigeria
2
Institute of Pharmacy, Pharmaceutical and Medicinal Chemistry, University of Greifswald, 17487 Greifswald, Germany
*
Authors to whom correspondence should be addressed.
Academic Editors: Luisa Tesoriere, Alessandro Attanzio and Riccardo Petrelli
Molecules 2020, 25(4), 849; https://doi.org/10.3390/molecules25040849 (registering DOI)
Received: 30 December 2019 / Revised: 5 February 2020 / Accepted: 7 February 2020 / Published: 14 February 2020
(This article belongs to the Special Issue Cytotoxic Activity of Plant Extracts)
In western Africa ethnomedicine, Lannea barteri Oliv. (Anacardiaceae) is believed to have activity against gastrointestinal, neurological and endocrine diseases. Previous studies on this plant have revealed antimicrobial, anticholinestrase, anticonvulsant, antioxidant and anti-inflammatory activities. However, the anticancer potential of L. barteri has not been studied to date. The aim of this study was to evaluate the anticancer potential of hot and cold extracts and silica gel column chromatographic fractions of L. barteri leaf and stem bark. The extracts and fractions were tested for anticancer activity by using the crystal violet cell proliferation assay on four adherent human carcinoma cell lines—5637 (bladder), KYSE 70 (oesophagus), SiSo (cervical) and HepG2 (hepatic). The inhibitory concentration (IC50) of fractions IH, 1I, 2E and 2F were: 3.75 ± 1.33, 3.88 ± 2.15, 0.53 ± 0.41, and 0.42 ± 0.45 µg/mL against KYSE 70 and 1.04 ± 0.94, 2.69 ± 1.17, 2.38 ± 3.64, 2.17 ± 1.92 µg/mL against SiSo cell lines respectively. Fraction 2E showed weak apoptotic activity at double the IC50 and some sign of cell cycle arrest in the G2/M phase. Thus, phytoconstituents of L. barteri leaf and stem bark can inhibit the proliferation of cancer cell lines indicating the presence of possible anticancer agents in this plant.
Keywords: Lannea barteri; leaf; stem bark; adherent human carcinoma cell lines; 5637; KYSE 70; SiSo; HepG2 Lannea barteri; leaf; stem bark; adherent human carcinoma cell lines; 5637; KYSE 70; SiSo; HepG2
Show Figures

Graphical abstract

  • Supplementary File 1:

    PDF-Document (PDF, 1078 KB)

  • Externally hosted supplementary file 1
    Doi: 10.5277/molecule:171819
    Link: https://molecule.org/record/202122
    Description: The HPLC result of fractions from Lannea barteri Oliv (Anacardiaceae) cold DCM leaf (fractions 1E-1K) and stem bark (fractions 2D-2J) extracts
MDPI and ACS Style

Mbaoji, F.N.; Behnisch-Cornwell, S.; Ezike, A.C.; Nworu, C.S.; Bednarski, P.J. Pharmacological Evaluation of the Anticancer Activity of Extracts and Fractions of Lannea barteri Oliv. (Anacardiaceae) on Adherent Human Cancer Cell Lines. Molecules 2020, 25, 849.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop